(19)
(11) EP 2 990 477 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
31.10.2018 Bulletin 2018/44

(45) Mention of the grant of the patent:
29.08.2018 Bulletin 2018/35

(21) Application number: 15186937.7

(22) Date of filing: 07.09.2012
(51) International Patent Classification (IPC): 
C12N 7/02(2006.01)
 B01D 61/14(2006.01)

(54)

REMOVAL OF CONTAMINATING VIRUSES FROM AAV PREPARATIONS

ENTFERNUNG VON KONTAMINATIONSVIREN AUS AAV-PRÄPARATEN

ÉLIMINATION DE VIRUS CONTAMINANTS DE PRÉPARATIONS D'AAV

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.09.2011 EP 11180594
08.09.2011 US 201161532176 P

(43) Date of publication of application:
02.03.2016 Bulletin 2016/09

(60) Divisional application:
18191023.3

(62) Application number of the earlier application in accordance with Art. 76 EPC:
12758663.4 / 2744895

(73) Proprietor: uniQure IP B.V.
1105 BP Amsterdam (NL)

(72) Inventors:
  • Hermens, Wilhelmus Theodorus Johannes Maria Christiaan
    1105 BP Amsterdam (NL)
  • Smith, James Patrick
    1105 BP Amsterdam (NL)

(74) Representative: Nederlandsch Octrooibureau 
P.O. Box 29720
2502 LS The Hague
2502 LS The Hague (NL)


(56) References cited: : 
WO-A1-2010/148143
 US-B1- 6 479 273
   
  • BURNOUF T ET AL: "NANOFILTRATION OF PLASMA-DERIVED BIOPHARMACEUTICAL PRODUCTS", HAEMOPHILIA, BLACKWELL SCIENCE, OXFORD, GB, vol. 9, no. 1, 1 January 2003 (2003-01-01) , pages 24-37, XP001181709, ISSN: 1351-8216, DOI: 10.1046/J.1365-2516.2003.00701.X
  • BLÜMEL J ET AL: "Wichtige Aspekte der Virussicherheit bei Neuartigen Therapien", BUNDESGESUNDHEITSBLATT - GESUNDHEITSFORSCHUNG - GESUNDHEITSSCHUTZ, SPRINGER, BERLIN, DE, vol. 53, no. 1, 26 November 2009 (2009-11-26), pages 38-44, XP019765204, ISSN: 1437-1588
  • BLÜMEL J: "Virus Safety Aspects of Advanced Therapies", DGRA-Symposium "Advanced Therapy Medicinal Product Development and Regenerative Medicine", Paul-Ehrlich-Institut, Langen, Germany, 25-26th November 2008, 26 November 2008 (2008-11-26), pages 1-18, XP055016970, Retrieved from the Internet: URL:http://www.dgra.de/fortbildung/pdf/wor kshops/20081125_pei/4-5-bluemel.pdf [retrieved on 2012-01-19]
  • RUEDA P ET AL: "Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 7-8, 22 November 2000 (2000-11-22), pages 726-734, XP27355281, ISSN: 0264-410X [retrieved on 2000-11-22]
  • KERN G: "Virus removal by filtration", BIOPHARM INTERNATIONAL, vol. 19, no. 10, 1 January 2006 (2006-01-01), pages 32-41, XP055017438,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).